Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
The US Food and Drug Administration (FDA) has approved Eli Lilly’s blockbuster type 2 diabetes therapy, Mounjaro (tirzepatide), as a…
28 Aug 2026
FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
Priovant Therapeutics has secured approval from the US Food and Drug Administration (FDA) for its oral therapy Lisraya (brepocitinib) in a rare autoimmune disease called dermatomyositis, becoming the first targeted…
28 Aug 2026
AusperBio raises $120m to progress hepatitis B therapies
AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B (CHB). The round was led…
28 Aug 2026
FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure…
27 Aug 2026
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
Biohaven and SK Pharmaceuticals have struck a licensing and partnership deal which will see the pair join forces to progress an epilepsy therapy that – if approved – could become…
27 Aug 2026
ESC 2026: True impact of poor medicine adherence laid bare in hypertensive patients
Patients who do not take blood pressure-lowering medication as prescribed are deriving little-to-no therapeutic benefit in cardiovascular disease, research shows. The study, full data of which will be presented at…
27 Aug 2026
FDA grants RPDD to ReviR’s RTX-117 for CMT
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT). The…